Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Valeria Pechtner"'
Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus
Publikováno v:
Diabetes & Metabolism. 43:501-511
Many people with type 2 diabetes mellitus (T2DM) fail to achieve glycaemic control promptly after diagnosis and do not receive timely treatment intensification. This may be in part due to 'clinical inertia', defined as the failure of healthcare provi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::501e6cf30ed2d36af79d8fb372537632
https://doi.org/10.1016/j.diabet.2017.06.003
https://doi.org/10.1016/j.diabet.2017.06.003
Publikováno v:
Diabetes Care. 38:2241-2249
OBJECTIVE This study compared the efficacy and safety of once-weekly dulaglutide, a glucagon-like peptide-1 receptor agonist, with daily insulin glargine, both combined with maximally tolerated doses of metformin and glimepiride in patients with type
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfc47244d59c99eb33e70c69c16070a4
https://doi.org/10.2337/dc14-1625
https://doi.org/10.2337/dc14-1625
Publikováno v:
Diabetes/metabolism research and reviews. 35(1)
Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are an important class of drugs with a well-established efficacy and safety profile in patients with type 2 diabetes mellitus. Agents in this class are derived from either exendin-4 (a compound
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a7950a4aa2ceb4dae60e36807aac29c
https://pubmed.ncbi.nlm.nih.gov/30156747
https://pubmed.ncbi.nlm.nih.gov/30156747
Autor:
Federico Pérez Manghi, Santiago Tofe Povedano, Guillermo E. Umpierrez, Valeria Pechtner, Linda Shurzinske
Publikováno v:
Diabetes care. 37(8)
OBJECTIVE Compare the efficacy and safety of monotherapy with dulaglutide, a once-weekly GLP-1 receptor agonist, to metformin-treated patients with type 2 diabetes. The primary objective compared dulaglutide 1.5 mg and metformin on change from baseli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71d8fa10ef5e226a918acab692163cdc
https://pubmed.ncbi.nlm.nih.gov/24842985
https://pubmed.ncbi.nlm.nih.gov/24842985
Autor:
H. Gelhorn, O. Adetunji, J. Poon, KS Boye, Rosirene Paczkowski, Sarah E Curtis, Valeria Pechtner, E. Davies, R. Gentilella
Publikováno v:
Annales d'Endocrinologie. 77:504
Objectifs Evaluer selon leur âge, les preferences des patients diabetiques de type 2 (DT2) pour les caracteristiques des GLP-1RAs au Royaume-Uni. Methodes C’etait un modele de choix discret (MDC) chez des patients DT2 adultes naifs de traitement i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20ac8e98d291b53f173a54bff9ad1203
https://doi.org/10.1016/j.ando.2016.07.763
https://doi.org/10.1016/j.ando.2016.07.763
Publikováno v:
Diabetes & Metabolism. 42:A40
Objectif Evaluer la tolerance, la PK et la PD du dulaglutide chez le patient âge. Patients et Methodes Etude en double aveugle, parallele, chez 37 hommes et femmes (≥ 65 ans) atteints de DT2, randomises pour recevoir dulaglutide 0,5, 0,75, 1,5mg o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::583597771e18372d81852ad42a5d3257
https://doi.org/10.1016/s1262-3636(16)30152-5
https://doi.org/10.1016/s1262-3636(16)30152-5
Autor:
Guillermo E. Umpierrez, L. Fernandez Lando, Kevin M. Pantalone, Valeria Pechtner, Alan G. Zimmermann, A.K. wan
Publikováno v:
Diabetes & Metabolism. 42:A44
Objectif Le dulaglutide, un agoniste du recepteur du GLP-1 a administration hebdomadaire, a ete evalue dans les d'essais cliniques du programme AWARD, chez des patients adultes atteints d'un diabete de type 2. Dans 6 essais comparatifs (head to head)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::61e5ba63032db90b5703b8673e91f787
https://doi.org/10.1016/s1262-3636(16)30165-3
https://doi.org/10.1016/s1262-3636(16)30165-3
Autor:
F.J. Tinahones, R. Gentilella, S.T. Povedano, C. Nicolay, Valeria Pechtner, L.A. Vázquez, Jesús Reviriego
Publikováno v:
Annales d'Endocrinologie. 76:377
Objectifs DU, agoniste hebdomadaire du recepteur du GLP-1 (glucagon-like peptide-1) etait superieur a l’EX BID et non inferieur au LIR OD sur la reduction de l’HbA1c dans deux essais AWARD, dont nous presentons ici des donnees supplementaires d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c802f8d1f9b27689a613cc94cf3d1293
https://doi.org/10.1016/j.ando.2015.07.238
https://doi.org/10.1016/j.ando.2015.07.238
Publikováno v:
Diabetes & Metabolism. 41:A8
Objectif Determiner l'impact de la duree du diabete (DD) sur l'efficacite et la securite du dulaglutide et de l'insuline glargine chez des patients DT2. Patients et methodes Analyses post-hoc en sous-groupes de DD ( Resultats Les groupes etaient comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::39f6ddd195de099059567c6bb8503c7f
https://doi.org/10.1016/s1262-3636(15)30028-8
https://doi.org/10.1016/s1262-3636(15)30028-8
Autor:
Thomas Forst, George Grunberger, Valeria Pechtner, Stephen C. L. Gough, R. Shaginian, Laura Fernandez, Huan Wang
Publikováno v:
Canadian Journal of Diabetes. 38:S52
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::27627d1fde181a281edbee35d2b866f9
https://doi.org/10.1016/j.jcjd.2014.07.142
https://doi.org/10.1016/j.jcjd.2014.07.142